Cure8 research brief
The study points to SERPINE1-driven fibroblast senescence via cGAS–STING as a contributor to Crohn’s disease inflammation and shows that pharmacologic inhibition (TM5441) reduced inflammation in a mouse model, suggesting a possible new therapeutic avenue to explore.
Researchers in IBD biology and drug discovery; clinicians interested in emerging molecular targets; informed patients tracking translational Crohn’s research.
The authors analyzed single-cell and bulk transcriptomes from Crohn’s disease patients to find a localized SERPINE1+ fibroblast population with high senescence signals and pro-inflammatory secretions.
They present mechanistic data linking TNF-α–producing macrophages to fibroblast senescence, with SERPINE1 sustaining the senescent state through activation of the cGAS–STING pathway.
The team tested a selective SERPINE1 inhibitor, TM5441, in a DSS-induced colitis mouse model and report that treatment reduced cGAS–STING–mediated senescence and attenuated colitis severity in that model. These are preclinical findings reported in an academic article (abstract-level content provided here).
Results are from transcriptomic analyses and preclinical experiments (cell co-cultures and a DSS mouse colitis model). This is mechanistic and early-stage; it does not demonstrate clinical benefit in humans.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.
TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...
Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...
